穆峰达^® （替尔泊肽注射液）

2 型糖尿病患者接受替尔泊肽治疗后负荷后脂质反应的改善

Improvements in Post-Challenge Lipid Response following Tirzepatide Treatment in Patients with Type 2 Diabetes

发表日期：2023-11-23

一项评估替尔泊肽治疗中国2型糖尿病患者的安全性、药代动力学和药效学的I期研究

A phase I study to evaluate safety, PK and PD of Tirzeptide in Chinese T2DM patients

发表日期：2023-06-07

替尔泊肽可降低 2 型糖尿病患者的食欲、能量摄入和脂肪量

Tirzepatide reduces appetite, energy intake and fat mass in people with T2D

发表日期：2023-03-01

肝损伤对 GIP 和 GLP-1 双受体激动剂替尔泊肽药代动力学的影响

Effects of Hepatic Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

发表日期：2022-06-08

皮下注射替尔泊肽与安慰剂或司美格鲁肽对成人 2 型糖尿病患者胰岛功能和胰岛素敏感性的影响：一项多中心、随机、双盲、平行臂、1 期临床试验

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

发表日期：2022-04-22

皮下注射替尔泊肽与安慰剂联合滴定甘精胰岛素对 2 型糖尿病患者血糖控制的影响：SURPASS-5 随机临床试验

Effects of Renal Impairment on the Pharmacokinetics of the Dual GIP and GLP-1 Receptor Agonist Tirzepatide

发表日期：2022-02-08

一项针对日本 2 型糖尿病受试者的替尔泊肽多次给药剂量递增1期临床研究

A phase 1 multiple-ascending dose study of tirzepatide in Japanese participants with type 2 diabetes

发表日期：2021-10-13

新型葡萄糖依赖性促胰岛素多肽和胰高糖素样肽 1 (GLP-1) 受体激动剂替尔泊肽可短暂延迟胃排空，与选择性长效 GLP-1 受体激动剂类似

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP ‐1 receptor agonists

发表日期：2020-06-10

随机临床试验：SYNERGY-NASH 2b期试验设计，评估替尔泊肽作为治疗代谢功能障碍相关脂肪肝的药物，并修改筛选策略以减少筛选失败

Randomised Clinical Trial: Design of the SYNERGY-NASH Phase 2b Trial to Evaluate Tirzepatide as a Treatment for Metabolic Dysfunction-Associated Steatohepatitis and Modification of Screening Strategy to Reduce Screen Failures

发表日期：2024-05-20

Tirzepatide（一种双重 GIP 和 GLP-1 RA）对 2 型糖尿病受试者血脂和代谢物谱的影响

Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects with Type 2 Diabetes

发表日期：2021-10-05

葡萄糖依赖性促胰岛素多肽和胰高糖素样肽 1 双受体激动剂替尔泊肽可改善 2 型糖尿病患者的心血管风险生物标志物：一项事后分析

The dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist tirzepatide improves cardiovascular risk biomarkers in patients with type 2 diabetes: A post hoc analysis

发表日期：2021-09-20

GIP 和 GLP-1 双受体激动剂替尔泊肽改善 2 型糖尿病的 β 细胞功能和胰岛素敏感性

Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-Cell Function and Insulin Sensitivity in Type 2 Diabetes

发表日期：2020-11-24

葡萄糖依赖性促胰岛素肽受体和胰高血糖素样肽 1 双受体激动剂替尔泊肽可改善 2 型糖尿病患者与胰岛素抵抗和心血管风险相关的脂蛋白生物标志物

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

发表日期：2020-08-16

新型 GIP 和 GLP-1 双受体激动剂替尔泊肽对 2 型糖尿病患者非酒精性脂肪性肝炎生物标志物的影响

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

发表日期：2020-04-14

替尔泊肽（一种葡萄糖依赖性促胰岛素肽和胰高血糖素样肽 1 双受体激动剂）对 2 型糖尿病患者的疗效和耐受性：一项为期 12 周、随机、双盲、安慰剂对照研究，旨在评估不同的剂量递增方案

Efficacy and tolerability of tirzepatide, a dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist in patients with type 2 diabetes: A 12‐week, randomized, double‐blind, placebo‐controlled study to evaluate different dose‐escalation regimens

发表日期：2020-01-27

通过替尔泊肽实现血糖正常：SURPASS 1-4 试验分析

Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials

发表日期：2024-09-06

替尔泊肽对2型糖尿病患者体脂分布模式的影响

Effect of tirzepatide on body fat distribution pattern in people with type 2 diabetes

发表日期：2024-03-26

替尔泊肽治疗阻塞性睡眠呼吸暂停：SURMOUNT -OSA 3 期试验的研究基础、设计和样本基线特征

Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial

发表日期：2024-03-26

替尔泊肽治疗 2 型糖尿病患者的疗效和安全性： SURPASS-AP-Combo 不同亚组的分析

Efficacy and Safety of Tirzepatide in Patients with Type 2 Diabetes: Analysis of SURPASS-AP-Combo by Different Subgroups.

发表日期：2024-03-18

替尔泊肽可降低体重指数≥27 kg/m2 成人的 24 小时动态血压：SURMOUNT-1 动态血压监测子研究

Tirzepatide Reduces 24-Hour Ambulatory Blood Pressure in Adults with Body Mass Index ≥27 kg/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy

发表日期：2024-02-05

日本 2 型糖尿病患者接受替尔泊肽单药治疗后的代谢异常：3 期 SURPASS J-mono 的事后分析

Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.

发表日期：2024-02-04

替尔泊肽改善2型糖尿病患者的胰岛细胞功能和胰岛素敏感性标志物 (SURPASS-2)

Tirzepatide Improved Markers of Islet Cell Function and Insulin Sensitivity in People With T2D (SURPASS-2)

发表日期：2024-01-22

持续使用替尔泊肽治疗以维持成人肥胖患者减重效果：SURMOUNT-4 随机临床试验

Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial

发表日期：2023-12-11

SURPASS-1 单药治疗试验中停用替尔泊肽 4 周后对糖化血红蛋白和体重变化的影响

Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial

发表日期：2023-10-25

SURPASS 临床试验中接受替尔泊肽治疗的 2 型糖尿病患者的胃肠道不良事件和体重减轻

Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials

发表日期：2023-10-18

替尔泊肽与度拉糖肽在日本2型糖尿病患者中的治疗满意度和生活质量：：SURPASS J-mono 试验的探索性评估

Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-Mono Trial

发表日期：2023-10-16

在超重或肥胖成人中，进行强化生活方式干预后使用替尔泊肽治疗：SURMOUNT-3 3 期试验

Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial

发表日期：2023-10-15

SURPASS 1-4 中 2 型糖尿病成人患者使用替尔泊肽后体重减轻 ≥15% 的预测因子及心脏代谢危险因素相关变化

Predictors of ≥15% Weight Reduction and Associated Changes in Cardiometabolic Risk Factors with Tirzepatide in Adults with Type 2 Diabetes in SURPASS 1-4

发表日期：2023-10-12

替尔泊肽与度拉糖肽在日本2型糖尿病患者中的血糖控制、体重和安全性比较（按基线HbA1c水平）：SURPASS J-mono研究的亚组分析

Glycemic control, bodyweight, and safety of tirzepatide versus dulaglutide by baseline HbA1c in Japanese patients with type 2 diabetes: A subgroup analysis of the SURPASS J-mono study

发表日期：2023-10-04

替尔泊肽与赖脯胰岛素联合基础胰岛素治疗 2 型糖尿病：SURPASS-6 随机临床试验

Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial

发表日期：2023-10-03

替尔泊肽和度拉糖肽对 2 型糖尿病合并动脉粥样硬化性心血管疾病参与者主要不良心血管事件的比较：SURPASS-CVOT 设计和基线特征

Comparison of Tirzepatide and Dulaglutide on Major Adverse Cardiovascular Events in Participants with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: SURPASS-CVOT Design and Baseline Characteristics

发表日期：2023-09-25

替尔泊肽的免疫原性对药代动力学、疗效和安全性的影响：3 期研究数据分析

Tirzepatide Immunogenicity on Pharmacokinetics, Efficacy, and Safety: Analysis of Data From Phase 3 Studies.

发表日期：2023-09-13

使用替尔泊肽实现血糖正常化：SURPASS 1-4 试验的分析

Achieving Normoglycemia with Tirzepatide: Analysis of SURPASS 1-4 trials

发表日期：2023-09-06

替尔泊肽治疗西班牙裔/拉丁裔 2 型糖尿病患者：一项SURPASS研究的亚组分析

Tirzepatide in Hispanic/Latino Patients with Type 2 Diabetes: A Subgroup Analysis of the SURPASS Program

发表日期：2023-08-21

SURPASS 临床试验项目中接受替尔泊肽治疗的 2 型糖尿病患者的患者报告结局

Patient‐Reported Outcomes in People with Type 2 Diabetes Receiving Tirzepatide in the SURPASS Clinical Trial Programme

发表日期：2023-08-01

每周一次替尔泊肽用于治疗 2 型糖尿病患者的肥胖症 (SURMOUNT-2)：一项双盲、随机、多中心、安慰剂对照 3 期试验

Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

发表日期：2023-06-23

替尔泊肽 10 和 15mg 与司美格鲁肽 2.4mg 治疗肥胖症的比较：间接治疗比较

Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

发表日期：2023-06-21

替尔泊肽与甘精胰岛素对基于胱抑素 C 的肾功能的影响：SURPASS-4 的事后分析

Effects of Tirzepatide Versus Insulin Glargine on Cystatin C-Based Kidney Function: A SURPASS-4 Post-Hoc Analysis

发表日期：2023-06-02

2 型糖尿病患者接受替尔泊肽治疗后体重变化与血糖控制之间的关系：一项SURPASS 临床试验项目的事后评估

Relationship Between Body Weight Change and Glycemic Control with Tirzepatide Treatment in People with Type 2 Diabetes: A Post Hoc Assessment of the SURPASS Clinical Trial Program

发表日期：2023-05-29

替尔泊肽与甘精胰岛素作为亚太地区 2 型糖尿病二线或三线治疗的对比：SURPASS-AP-Combo 试验

Tirzepatide versus insulin glargine as second-line or third-line therapy in type 2 diabetes in the Asia-Pacific region: the SURPASS-AP-Combo trial

发表日期：2023-05-25

替尔泊肽作为单一疗法可改善 2 型糖尿病的 β 细胞功能和胰岛素敏感性标志物 (SURPASS-1)

Tirzepatide as monotherapy improved markers of beta-cell function and insulin sensitivity in type 2 diabetes (SURPASS-1)

发表日期：2023-04-22

2 型糖尿病患者使用替尔泊肽达到血糖和体重减轻阈值的时间：SURPASS-2 和 SURPASS-3 预先设定的探索性分析

Time to Reach Glycaemic and Body Weight Loss Thresholds with Tirzepatide in Patients With Type 2 Diabetes: A Pre-planned Exploratory Analysis of SURPASS-2 and SURPASS-3

发表日期：2023-03-31

替尔泊肽降低 2 型糖尿病患者的收缩压：来自 SURPASS 临床项目的见解

Systolic Blood Pressure Reduction with Tirzepatide in Patients with Type 2 Diabetes: Insights from SURPASS Clinical Program

发表日期：2023-03-24

替尔泊肽治疗肥胖：SURMOUNT 临床研发项目的基本原理和设计

Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program

发表日期：2022-12-07

在 替尔泊肽3期研究（SURPASS项目）中对东亚 2 型糖尿病参与者的年龄和体重指数亚组进行安全性和有效性分析

Safety and efficacy analyzes across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS program)

发表日期：2022-11-22

每周一次的葡萄糖依赖性促胰岛素多肽和胰高糖素样肽 1 双受体激动剂替尔泊肽在 2 型糖尿病中实现血糖目标，同时减轻体重且无低血糖：一项SURPASS-1 至 -5 研究的事后分析

Achievement of glycemic targets with weight loss and without hypoglycemia in type 2 diabetes with once-weekly GIP and GLP-1 receptor agonist tirzepatide: a post-hoc analysis of the SURPASS-1 to -5 studies

发表日期：2022-11-13

一周一次替尔泊肽治疗与度拉糖肽治疗在日本2型糖尿病患者中的药效动力学变化（SURPASS J-mono子研究）

Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy)

发表日期：2022-10-02

SURPASS-4 试验中替尔泊肽与甘精胰岛素对 2 型糖尿病肾脏结局的影响：一项开放标签、随机、3 期试验的事后分析

Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial

发表日期：2022-09-21

转向活性对照试验以评估 2 型糖尿病药物的心血管安全性和有效性

Transitioning to Active-Controlled Trials to Evaluate Cardiovascular Safety and Efficacy of Medications for Type 2 Diabetes

发表日期：2022-08-24

替尔泊肽单药治疗对比度拉糖肽治疗日本 2 型糖尿病患者的疗效和安全性（SURPASS J-mono）：一项双盲、随机、多中心、3 期试验

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes mellitus (SURPASS J-mono): a double-blind, randomised, multicentre, phase 3 trial

发表日期：2022-07-30

替尔泊肽作为单一口服降糖药物的补充治疗日本 2 型糖尿病患者的安全性和有效性（SURPASS J-combo）：一项多中心、随机、开放标签、平行分组的3 期试验

Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial

发表日期：2022-07-30

每周一次替尔泊肽治疗肥胖

Tirzepatide Once Weekly for the Treatment of Obesity

发表日期：2022-06-04

替尔泊肽 5、10 和 15mg 与司美格鲁肽 2mg 在 2 型糖尿病患者中的疗效：调整后的间接治疗比较

Efficacy of tirzepatide 5, 10, and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: an adjusted indirect treatment comparison

发表日期：2022-05-19

每周一次的替尔泊肽与每日一次的德谷胰岛素对通过连续血糖监测测量的成人 2 型糖尿病患者血糖控制的疗效 (SURPASS-3 CGM)：一项随机、开放标签、平行分组、3 期 SURPASS 的子研究

Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control captured with continuous glucose monitoring in participants with type 2 diabetes (SURPASS-3 CGM): A substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

发表日期：2022-04-22

替尔泊肽与德谷胰岛素对 2 型糖尿病患者肝脏脂肪含量和腹部脂肪组织的影响 (SURPASS-3 MRI)：一项随机、开放、平行分组 3 期 SURPASS-3 试验的子研究

Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in patients with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

发表日期：2022-04-22

皮下注射替尔泊肽与安慰剂联合滴定甘精胰岛素对 2 型糖尿病患者血糖控制的影响：SURPASS-5 随机临床试验

Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes The SURPASS-5 Randomized Clinical Trial

发表日期：2022-02-08

替尔泊肽与甘精胰岛素治疗心血管风险增加的2 型糖尿病的对比 (SURPASS-4)：一项随机、开放标签、平行分组、多中心的3 期试验

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

发表日期：2021-10-18

每周一次的替尔泊肽与每日一次的德谷胰岛素作为接受二甲双胍（联合或不联合SGLT2抑制剂）治疗 2 型糖尿病患者的补充治疗(SURPASS-3)：一项随机、开放标签、平行分组 3 期试验

Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial

发表日期：2021-08-06

新型 GIP 和 GLP-1 双受体激动剂替尔泊肽对 2 型糖尿病患者的疗效和安全性 (SURPASS-1)：一项双盲、随机、3 期试验

Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial

发表日期：2021-06-27

替尔泊肽与每周一次司美格鲁肽治疗 2 型糖尿病患者的对比

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes

发表日期：2021-06-25

从胰高糖素样肽 1 受体激动剂转换为替尔泊肽5mg：治疗最初 12 周的临床预期

Switching to Tirzepatide 5 mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment

发表日期：2024-05-08

了解伴有代谢合并症的非酒精性脂肪性肝炎对成人的影响：一项真实世界的定性研究

Understanding the Impact of Non-alcoholic Steatohepatitis with Metabolic Comorbidities on Adults: A Real-World Qualitative Study

发表日期：2024-02-29

2型糖尿病和肥胖在非酒精性脂肪肝/非酒精性脂肪性肝炎疾病活动和进展中的作用

The roles of type 2 diabetes and obesity in disease activity and progression of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis

发表日期：2023-12-01

检查过度肥胖的风险——机器学习预测肥胖相关并发症

EXIST: EXamining rIsk of excesS adiposiTy-Machine learning to predict obesity-related complications

发表日期：2023-08-23

真实世界中主要不依从抗肥胖药物的情况

Real-world primary nonadherence to antiobesity medications

发表日期：2023-08-18

超重或肥胖患者的体重管理治疗模式：行政索赔数据的回顾性队列研究

Weight management treatment modalities in patients with overweight or obesity: A retrospective cohort study of administrative claims data

发表日期：2023-05-24

退出访视：对替尔泊肽治疗 2 型糖尿病临床试验中的患者体验的研究

Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes

发表日期：2022-05-06

与 2 型糖尿病和肥胖症患者体重减轻相关的健康状态效用量表

Health state utilities associated with weight loss in type 2 diabetes and obesity

发表日期：2021-12-19

患者对糖尿病注射治疗特征的看法和偏好

Patient Perceptions of and Preferences between Characteristics of Injectable Diabetes Treatments

发表日期：2021-07-23

2 型糖尿病患者口服降糖药的失效时间：一项回顾性队列研究

Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study

发表日期：2021-04-10

与赖脯胰岛素相比，替尔泊肽改善了接受基础胰岛素治疗且血糖控制不佳的 2 型糖尿病成人患者的健康相关生活质量：一项随机对照 3b 期临床试验 (SURPASS-6)

Tirzepatide Improved Health-Related Quality of Life Compared with Insulin Lispro in Basal Insulin-Treated Adults with Type 2 Diabetes and Inadequate Glycaemic Control: A Randomised Controlled Phase 3b Trial (SURPASS-6)

发表日期：2024-07-15

替尔泊肽 10 和 15 mg 与司美格鲁肽 2.0 mg在美国 2 型糖尿病患者中的长期成本效益分析

TIRZEPATIDE 10 AND 15 mg VERSUS SEMAGLUTIDE 2.0 mg: A LONG-TERM COST-EFFECTIVENESS ANALYSIS IN PATIENTS WITH TYPE 2 DIABETES IN THE UNITED STATES

发表日期：2024-02-03

替尔泊肽可降低肥胖或超重成人患动脉粥样硬化性心血管疾病的预测风险并改善心脏代谢危险因素：SURMOUNT-1 事后分析

Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis

发表日期：2023-11-06

对成人 2 型糖尿病患者的血糖控制与总医疗费用之间关系的经济评估：回顾性队列研究

An Economic Evaluation of The Relationship Between Glycemic Control and Total Healthcare Costs for Adults with Type 2 Diabetes: Retrospective Cohort Study

发表日期：2023-11-01

体重变化对 T2D 血糖控制和代谢参数的影响：基于真实世界数据的美国回顾性研究

Impact of Weight Change on Glycemic Control and Metabolic Parameters in T2D: A Retrospective US Study Based on Real-World Data

发表日期：2023-11-01

在美国2型糖尿病患者中，使用替尔泊肽与司美格鲁肽1mg治疗达到治疗目标的患者成本及需要治疗的人数

Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States

发表日期：2023-09-28

替尔泊肽可降低肥胖或超重人群患 2 型糖尿病的预测风险：SURMOUNT-1 试验的事后分析

Tirzepatide reduces the predicted risk of developing type 2 diabetes in people with obesity or overweight: Post hoc analysis of the SURMOUNT-1 trial

发表日期：2023-09-12

伴或不伴糖尿病前期的美国肥胖人群的五年发病率和死亡率

Five-year morbidity and mortality rates in a U.S. population with obesity with and without prediabetes

发表日期：2023-03-17

替尔泊肽与司美格鲁肽 1.0mg 治疗美国 2 型糖尿病的长期成本效益分析

Long-term cost-effectiveness analysis of tirzepatide versus semaglutide 1.0 mg for the management of type 2 diabetes in the US

发表日期：2023-01-18

美国 2 型糖尿病患者的肥胖和血糖控制：使用保险理赔数据的回顾性队列研究

Obesity and glycemic control among people with type 2 diabetes in the United States: A retrospective cohort study using insurance claims data

发表日期：2021-06-19

2 型糖尿病患者的 HbA1c 和体重指数趋势：来自 2012-2019 年美国数据库的证据

Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a U.S. Database 2012-2019

发表日期：2021-06-02